MRP ₹159
(Inclusive of all Taxes)
₹23.9 Cashback (15%)
Prescription drugWhats That
Composition :
CLINDAMYCIN-1%W/V
Manufacturer/Marketer :
USV Pvt Ltd
Consume Type :
TOPICAL
Return Policy :
Not Returnable
Expires on or after :
Drug-Drug Interactions
No Drug - Drug interactions found in our data. We may lack specific data on this medicine and are actively working to update our database. Consult your doctor for personalized advice
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Product Substitutes
Author Details
Drug-Diseases Interactions
CLINDAMYCIN-1%W/VOther bacterial intestinal infections
Severe
CLINDAMYCIN-1%W/VDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
Drug-Diseases Interactions
Login/Sign Up
CLINDAMYCIN-1%W/VOther bacterial intestinal infections
Severe
How does the disease interact with Erytop Lotion 25 ml:
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
Almost all antibacterial medications have been associated with reports of Clostridioides difficile-associated diarrhoea (CDAD), formerly known as pseudomembranous colitis. It can vary from mild diarrhoea to deadly colitis.
How to manage the interaction:
Clostridioides difficile-associated diarrhea (CDAD) ranging from mild diarrhoea to colitis has been reported during treatment with antibacterial agents. Therapy should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis and pseudomembranous colitis. Appropriate fluid and electrolyte management, protein supplementation, and antibacterial treatment of C difficile is advised.
CLINDAMYCIN-1%W/VDisorders related to short gestation and low birth weight, not elsewhere classified
Severe
How does the disease interact with Erytop Lotion 25 ml:
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
Benzyl alcohol is frequently used as a preservative in the formulation of multidose vials for parenteral medicines. Manufacturers of pharmaceuticals believe that using them in neonates, especially preterm and underweight newborns, is contraindicated. In low birth weight preterm newborns, the use of benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been linked to mortality and serious respiratory and metabolic problems.
How to manage the interaction:
Parenteral medications containing benzyl alcohol as a preservative are contraindicated in neonates, particularly premature infants and infants of low birth weight.
CLINDAMYCIN-1%W/VOther diseases of liver
Moderate
How does the disease interact with Erytop Lotion 25 ml:
The liver is the primary site of Erytop Lotion 25 ml metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Erytop Lotion 25 ml and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Erytop Lotion 25 ml therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Erytop Lotion 25 ml is primarily metabolized by the liver. Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
The liver is the primary site of Erytop Lotion 25 ml metabolism. Patients with significantly impaired hepatic function may have a rise in the blood concentration of Erytop Lotion 25 ml and a prolongation of the half-life. Additionally, the drug's usage may result in abnormal liver enzyme levels and jaundice. Patients with liver problems should receive Erytop Lotion 25 ml therapy with caution. When given every 8 hours, dosage modifications might not be required. However, with high-dose therapy, serum concentrations should be observed, and during prolonged therapy, regular liver function tests should be carried out.
How to manage the interaction:
Erytop Lotion 25 ml is primarily metabolized by the liver. Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with liver disease. Serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/VOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Erytop Lotion 25 ml:
Erytop Lotion 25 ml is partially removed by the kidney. Erytop Lotion 25 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Erytop Lotion 25 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with severely impaired renal function. Serum Erytop Lotion 25 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Erytop Lotion 25 ml is partially removed by the kidney. Erytop Lotion 25 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Erytop Lotion 25 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with severely impaired renal function. Serum Erytop Lotion 25 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
CLINDAMYCIN-1%W/VOther disorders of kidney and ureter, not elsewhere classified
Moderate
How does the disease interact with Erytop Lotion 25 ml:
Erytop Lotion 25 ml is partially removed by the kidney. Erytop Lotion 25 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Erytop Lotion 25 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with severely impaired renal function. Serum Erytop Lotion 25 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Erytop Lotion 25 ml is partially removed by the kidney. Erytop Lotion 25 ml should be used with caution in individuals with significantly impaired renal function. Dosage changes are probably to be required. Serum Erytop Lotion 25 ml concentrations should be monitored throughout high-dose therapy, and renal function tests should be conducted on a regular basis during extended medication.
How to manage the interaction:
Therapy with Erytop Lotion 25 ml should be administered cautiously in patients with severely impaired renal function. Serum Erytop Lotion 25 ml concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.
Have a query?
Alcohol
Caution
No interactions were found/established. Please consult your doctor if you have any concerns.
Pregnancy
Caution
Please consult your doctor before using Erytop Lotion if you are pregnant or planning to conceive.
Breast Feeding
Caution
Please consult your doctor before using Erytop Lotion if you are breastfeeding. If you need to apply the cream, gel or lotion on your breasts, don't do this shortly before giving a feed.
Driving
Safe if prescribed
Erytop Lotion has no or negligible influence on the ability to drive or use machines.
Liver
Caution
Let your doctor know if you have any history of liver diseases before using Erytop Lotion.
Kidney
Caution
Let your doctor know if you have any history of kidney diseases before using Erytop Lotion.
Children
Unsafe
Erytop Lotion is not recommended in children below 12 years of age.
